“The courage the Sontags have shown not only to battle brain cancer, but to engender a culture of risk taking and innovation to find new tactics to combat this disease is inspiring.”
Ben Deneen, Ph.D. ’11 DSA
Professor, Department of Neurosurgery
Professor, Center for Stem Cells & Regenerative Medicine
Baylor College of Medicine
Why Venture Philanthropy?
We make loans and equity investments to further our mission and expand the impact of our grant making programs. Our goal is to foster the advancement of promising technology by investing in early stage, high-risk/high-reward opportunities to attract financially motivated investors and accelerate the developmental pipeline.
We focus our resources solely on opportunities to advance our charitable mission. While we take chances in pursuit of impact, we also seek overall return of principal so we can recycle capital and maximize our long-term effectiveness. Our investments are typically structured as loans and equity investments, and we work with both for-profit and non-profit entities.
Fund Investment Profile
Areas of Interest
Therapeutics, Diagnostics, Medical Devices & Other Technologies.
What We Provide
IP Support, Startup Seed Capital, Management Support, & Help Driving Pipeline Expansion/Repurposing.
Flexible, long-term/patient investments, and access to a network of top investment professionals, clinicians, and researchers.
AiM Medical Robotics
AiM Medical Robotics is a neurosurgical robotics company that is working to bring high levels of precision, automation, and efficiency, to the complex environment of neurosurgery. This robot has potential applications for brain tumor biopsy, tumor ablation and many other procedures that could impact the health status of brain tumor patients.
Kiyatec is a functional precision oncology company using ex vivo 3D cell culture technology that can be utilized for gliomas in preclinical and clinical settings. This includes providing companies developing therapies an optimized in vitro assessment of drug-on-tumor cell interaction and oncologists with patient-tumor specific responses to therapeutics that could be used to treat gliomas.